Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
New versus current adalimumab formulation in active rheumatoid arthritis
2012-000535-36Phase 2Terminated
- Sponsor
- Abbott Laboratories
- Start
- Jun 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of adalimumab in rheumatoid arthritis (RA) (2 arms), sponsored by Abbott Laboratories. Primary endpoint: Comparison of new versus current adalimumab formulation. Started Jun 2012; status: terminated.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2012-000535-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000535-36.